Your browser is no longer supported. Please, upgrade your browser.
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Stats
Total: 28 #1
TickerCUR [NASD]
CompanyNeuralstem, Inc.
Market Cap53.39MEPS (ttm)-0.23
P/E-EPS this Y11.50%
Forward P/E-EPS next Y-9.10%
PEG-EPS past 5Y11.50%
P/S4244.44EPS next 5Y-
P/B11.80EPS Q/Q17.00%
Dividend-Sales Q/Q-50.00%
Insider Own2.80%Inst Own16.00%
Insider Trans-2.87%Inst Trans-0.48%
Short Float6.45%EarningsMay 06/b
Analyst Recom2.00Target Price8.00
Avg Volume158.70K52W Range0.52 - 2.37
May-03-16 08:24AM8:24 am Neuralstem prices 20 mln common stock offering at $0.40/share; gross proceeds expected to be ~$8 mln
May-03-16 08:22AMNeuralstem Prices Underwritten Public Offering of Securities PR Newswire
Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds. The company's stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical development products include NSI-189, which has completed Phase I clinical trial for the treatment of major depressive disorder, as well as is in Phase I clinical trial for the treatment of other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy; and NSI566 that has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GARR RICHARDCEOJan 27Option Exercise0.0019,80201,456,269Jan 28 04:00 PM
JOHE KARLChief Scientific OfficerNov 19Option Exercise0.00143,2470969,551Nov 20 04:11 PM
GARR RICHARDCEONov 19Option Exercise0.00138,12201,474,243Nov 20 04:14 PM
OLDAKER WILLIAM CLYDEDirectorNov 19Option Exercise0.0015,0000196,826Nov 20 04:16 PM
JOHE KARLChief Scientific OfficerNov 16Sale1.0925,00027,250826,304Nov 16 07:40 PM
TickerFWM [NASD]
CompanyFairway Group Holdings Corp.
IndustryGrocery Stores
Market Cap9.32MEPS (ttm)-1.01
P/E-EPS this Y65.40%
Forward P/E-EPS next Y69.70%
PEG-EPS past 5Y11.30%
P/S0.01EPS next 5Y15.00%
P/B-EPS Q/Q13.20%
Dividend-Sales Q/Q-7.00%
Insider Own1.31%Inst Own48.30%
Insider Trans0.00%Inst Trans-0.39%
Short Float12.69%EarningsMay 24/a
Analyst Recom2.30Target Price1.00
Avg Volume223.29K52W Range0.13 - 5.19
May-03-16 06:51AMFairway files for bankruptcy protection CNBC
May-03-16 03:02AM3:02 am Fairway Group Holdings initiates prepackaged Chapter 11 reorganization; store operations expected to continue
Fairway Group Holdings Corp., together with its subsidiaries, operates as a food retailer in the United States. The company offers fresh produce; Deli products, such as sandwiches, side dishes, toppings, platters, snacks, and main dishes; specialty and gourmet products; cheese; meat and chicken products; seafood products; bakery products comprising cookies, tarts, cupcakes, baguettes, and bagels; coffee; and kosher products. It also provides natural and organic foods, such as fruits and vegetables, natural and fresh juices, organic beef and organic chicken, organic peanut and almond butter, roasted coffees and loose teas, dried fruits and nuts, natural and organic groceries, cold cuts and cheeses, breads, nutritional bars and protein powders, health and beauty aids, milk, eggs, dairy alternatives, frozen foods, gluten-free products, baby food and baby care products, and cleaning products, as well as homeopathy, vitamins, and herbs supplements. In addition, the company offers conventional groceries, specialty foods, and wines and spirits. It operates 15 locations in New York, New Jersey, and Connecticut, including 4 Fairway Wines & Spirits locations. Fairway Group Holdings Corp. was founded in 1933 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Glickberg HowardDirectorOct 01Option Exercise0.0050,1330336,423Oct 02 01:57 PM
Glickberg HowardDirectorJul 09Option Exercise0.0028,1950286,290Jul 28 02:20 PM
Glickberg HowardDirectorJun 03Option Exercise0.00170,4650258,095Jun 05 05:39 PM
TickerWAC [NYSE]
CompanyWalter Investment Management Corp.
IndustryMortgage Investment
Market Cap269.64MEPS (ttm)-7.03
P/E-EPS this Y-138.90%
Forward P/E5.06EPS next Y-1.66%
PEG-EPS past 5Y-47.90%
P/S0.21EPS next 5Y-4.30%
P/B0.33EPS Q/Q-171.00%
Dividend-Sales Q/Q4.40%
Insider Own2.80%Inst Own92.00%
Insider Trans0.00%Inst Trans0.71%
Short Float16.69%EarningsMay 03/b
Analyst Recom3.90Target Price7.29
Avg Volume280.18K52W Range6.31 - 23.70
May-03-16 09:49AMWalter Investment Management Corp Earnings Call scheduled for 10:00 am ET today CCBN
May-03-16 07:14AMWALTER INVESTMENT MANAGEMENT CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Di EDGAR Online
May-03-16 07:07AMQ1 2016 Walter Investment Management Corp Earnings Release - Before Market Open CCBN
May-03-16 06:56AMWalter Investment reports 1Q loss AP
May-03-16 06:36AM6:36 am Walter Investment Mgmt reports Q1 (Mar) results, misses on revs
May-03-16 06:30AMWalter Investment Management Corp. Announces First Quarter 2016 Highlights and Financial Results PR Newswire
May-03-16 06:13AMWALTER INVESTMENT MANAGEMENT CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
Walter Investment Management Corp., a diversified mortgage banking firm, focuses primarily on the servicing and origination of residential loans in the United States. The company operates in three segments: Servicing, Originations, and Reverse Mortgage. The Servicing segment performs services for third-party credit owners of mortgage loans, as well as its mortgage loan portfolio. This segment also operates complementary businesses consisting of an insurance agency serving residential loan borrowers and credit owners; and a collections agency that performs collections of post charge-off deficiency balances for third parties and the company. In addition, it holds the assets and mortgage-backed debt of the residual trusts. The Originations segment originates and purchases mortgage loans for third parties while retaining the servicing rights. The Reverse Mortgage segment primarily focuses on the origination, securitization, and servicing of reverse loans. This segment also performs servicing for third-party credit owners of reverse loans; and provides other services for the reverse mortgage market, such as real estate owned property management and disposition. Walter Investment Management Corp. was founded in 1958 and is based in Tampa, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Baker Street Capital Managemen10% OwnerJun 26Buy22.8247,2001,077,0717,325,898Jun 29 04:10 PM
Baker Street Capital Managemen10% OwnerJun 25Buy22.8167,4001,537,2867,278,698Jun 25 07:17 PM
Baker Street Capital Managemen10% OwnerJun 24Buy22.9430,000688,1227,211,298Jun 25 07:17 PM
Baker Street Capital Managemen10% OwnerJun 23Buy23.23100,1142,325,4387,181,298Jun 25 07:17 PM
OBRIEN MARK JChairman & CEOJun 18Option Exercise6.998,75861,218495,508Jun 22 04:34 PM
CompanyOn Deck Capital, Inc.
IndustryCredit Services
Market Cap582.83MEPS (ttm)-0.03
P/E-EPS this Y97.00%
Forward P/E23.65EPS next Y1964.71%
PEG-EPS past 5Y0.00%
P/S2.29EPS next 5Y-
P/B1.79EPS Q/Q46.20%
Dividend-Sales Q/Q33.90%
Insider Own1.40%Inst Own78.10%
Insider Trans-2.48%Inst Trans-0.01%
Short Float7.67%EarningsMay 02/a
Analyst Recom2.10Target Price13.48
Avg Volume329.10K52W Range6.05 - 20.39
May-03-16Downgrade FBR Capital Outperform → Mkt Perform $11 → $6.50
May-03-16Downgrade Needham Buy → Hold
May-03-16Downgrade Sterne Agee CRT Neutral → Underperform
May-03-16Reiterated Compass Point Neutral $7.50 → $6
May-03-16Reiterated Stifel Buy $11 → $10
May-03-16 08:50AMTop Analyst Upgrades and Downgrades: CenturyLink, International Paper, Kroger, On Deck Capital, Phillips 66, United Tech and More at 24/7 Wall St.
May-03-16 07:01AMNew Lending Data From OnDeck Kicks Off Small Business Week PR Newswire
On Deck Capital, Inc. operates an online platform for small business lending in the United States. It offers short term loans, long term loans, and flexible lines of credit. The company was incorporated in 2006 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Katzenberg HowardChief Financial OfficerDec 21Sale10.7725,000269,268422,439Dec 22 04:16 PM
CompanySagent Pharmaceuticals, Inc.
IndustryDrugs - Generic
Market Cap398.78MEPS (ttm)-0.67
P/E-EPS this Y-159.80%
Forward P/E16.49EPS next Y85.68%
PEG-EPS past 5Y15.90%
P/S1.25EPS next 5Y32.60%
P/B1.54EPS Q/Q-166.70%
Dividend-Sales Q/Q-0.60%
Insider Own1.10%Inst Own76.80%
Insider Trans-77.76%Inst Trans-5.06%
Short Float6.48%EarningsMay 03/b
Analyst Recom2.40Target Price20.71
Avg Volume391.69K52W Range11.36 - 26.47
May-03-16 08:02AMSAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
May-03-16 07:52AMSagent reports 1Q loss AP
May-03-16 07:32AM7:32 am Sagent Pharma beats by $0.02, misses on revs; guides FY16 revs in-line
May-03-16 07:30AMSagent Pharmaceuticals Reports First Quarter 2016 Financial Results GlobeNewswire
May-03-16 07:07AMQ1 2016 Sagent Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
Sagent Pharmaceuticals, Inc. develops, sources, manufactures, and markets injectable pharmaceuticals in North America. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection, and pyelonephritis in adults of age 18 years or older. It also provides oncology products consisting of Leucovorin Calcium, a folic acid derivative used to prevent harmful effects of methotrexate when methotrexate is used to treat cancer; and Zoledronic Acid, a bisphosphonate given intravenously to prevent skeletal fractures in patients with multiple myeloma and prostate cancer, as well as for treating osteoporosis. In addition, the company offers critical care products comprising Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis; and Propofol, a sedative used to induce and maintain general anesthesia during surgical procedures. As of December 31, 2015, its product portfolio included 55 marketed products in an aggregate of 181 presentations, as well as 48 products in an aggregate of 98 presentations in the United States. Sagent Pharmaceuticals, Inc. sells its products to hospitals, integrated delivery networks, and alternative site facilities through pharmaceutical wholesalers and specialty distributors. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vivo Ventures V, LLC10% OwnerApr 21Sale13.552,00527,16834,961Apr 25 04:34 PM
Vivo Ventures VI, LLC10% OwnerApr 21Sale13.552,31631,38225,320Apr 25 04:37 PM
Yanai ShlomoDirectorApr 15Option Exercise0.007420742Apr 18 11:58 AM
FLANAGAN ROBERT JDirectorFeb 18Option Exercise0.00930010,183Feb 22 12:41 PM
Krizman AnthonyDirectorFeb 18Option Exercise0.0093005,080Feb 22 12:41 PM
CompanyProNAi Therapeutics, Inc.
Market Cap173.14MEPS (ttm)-115.64
P/E-EPS this Y94.10%
Forward P/E-EPS next Y-0.50%
PEG-EPS past 5Y0.00%
P/S-EPS next 5Y23.40%
P/B1.16EPS Q/Q26.70%
Dividend-Sales Q/Q-
Insider Own0.50%Inst Own61.40%
Insider Trans-Inst Trans-0.35%
Short Float4.02%EarningsMay 05/b
Analyst Recom1.30Target Price32.75
Avg Volume115.85K52W Range5.40 - 33.75
May-02-16 04:53PM4:53 pm ProNAi Therapeutics Chief Medical Officer Richard Messmann resigns, effective May 26
May-02-16 04:29PMPRONAI THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
ProNAi Therapeutics, Inc., a clinical-stage oncology company, develops and commercializes drugs based on its DNA interference (DNAi) technology platform for patients with cancer and hematological malignancies. Its lead DNAi product candidate is PNT2258, a proprietary formulation of PNT100, a single-stranded 24-base DNAi oligonucleotide, which is in Phase II clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and Richter's transformed chronic lymphocytic leukemia. The company was formerly known as Phenome Systems, Inc. and changed its name to ProNAi Therapeutics, Inc. in April 2004. ProNAi Therapeutics, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
TickerYGE [NYSE]
CompanyYingli Green Energy Holding Co. Ltd.
IndustrySemiconductor - Specialized
Market Cap71.46MEPS (ttm)-14.10
P/E-EPS this Y39.70%
Forward P/E-EPS next Y84.70%
PEG-EPS past 5Y-14.30%
P/S0.04EPS next 5Y-
P/B-EPS Q/Q-100.60%
Dividend-Sales Q/Q-20.30%
Insider Own83.40%Inst Own18.10%
Insider Trans0.00%Inst Trans3.81%
Short Float4.99%EarningsApr 28/b
Analyst Recom3.70Target Price5.87
Avg Volume111.92K52W Range2.93 - 18.80
Apr-29-16 07:24AMChinese solar company Yingli delays annual report Reuters
Apr-29-16 06:53AMYingli Signals Bankruptcy Risk as Loss Widens, Sales Fall at Bloomberg
Apr-29-16 06:33AM6:33 am Yingli Green Energy files extension for filing annual report, estimates FY15 net loss of RMB 5.8-5.9 bln, FY15 gross profit of RMB 1.1-1.2 bln
Apr-29-16 06:30AMYingli Green Energy Filed Extension for 2015 Form 20-F and Disclosed Preliminary Financial Results for Full Year 2015 PR Newswire
Yingli Green Energy Holding Company Limited, together with its subsidiaries, designs, develops, markets, manufactures, sells, and installs photovoltaic (PV) products in the People's Republic of China and internationally. The company offers polysilicon ingots and blocks, polysilicon wafers, PV cells, PV modules, and integrated PV systems; and develops and operates solar projects. It primarily sells its PV modules to distributors, wholesalers, power plant developers and operators, and PV system integrators under the brand names Yingli and Yingli Solar. Yingli Green Energy Holding Company Limited was founded in 1998 and is headquartered in Baoding, the People's Republic of China.
CompanySizmek Inc.
IndustryAdvertising Agencies
Market Cap81.32MEPS (ttm)-4.64
P/E-EPS this Y-22.90%
Forward P/E-EPS next Y35.40%
PEG-EPS past 5Y0.00%
P/S0.47EPS next 5Y-
P/B0.63EPS Q/Q-
Dividend-Sales Q/Q13.50%
Insider Own14.50%Inst Own50.10%
Insider Trans0.00%Inst Trans1.56%
Short Float3.84%EarningsMay 12/a
Analyst Recom3.00Target Price3.75
Avg Volume102.45K52W Range2.60 - 7.91
Apr-27-16 09:20AMFinding Opportunities in Marketing Technology and the Ad Tech Industry Accesswire
Sizmek Inc. operates an online ad campaign management and distribution platform that provides online advertising services worldwide. It operates an online campaign management platform, Sizmek MDX that helps advertisers, agencies, and publishers in simplifying the complexities of managing their advertising budgets across multiple online media channels and formats, such as desktop, mobile, rich media, social media, in-stream video, interactive video, display, and search. The Sizmek MDX platform provides its customers with an easy-to-use, and end-to-end solution to enhance planning, creative, delivery, measurement, and optimization of online media campaigns. The company's online campaign management product and service offerings span the lifecycle of an advertising campaign, including creative authoring, which provide creative designers and producers with tools and services to manage a campaign's creative development lifecycle, from initial design, to inclusion of interactive features, to adaptation for analytics and ad insertion, and to integration with campaign management and ad serving processes; analytics and monitoring; and Peer 39, a provider of data based on the content and structure of Web pages. Its platform also offers programmatic managed services; customized services, such as trafficking, creative production, quality assurance, research, analysis and custom reporting, and data integration services; and customer support services. In addition the company provides data based on the content and structure of Web pages for enhancing the relevance and effectiveness of online display advertising. Sizmek Inc. sells its offerings primarily through a direct sales force or through third-party selling agents. The company, formerly known as The New Online Company, is based in Austin, Texas.
CompanyImmunoGen, Inc.
Market Cap709.91MEPS (ttm)-1.38
P/E-EPS this Y15.40%
Forward P/E-EPS next Y-6.00%
PEG-EPS past 5Y4.00%
P/S12.48EPS next 5Y-
P/B-EPS Q/Q-342.80%
Dividend-Sales Q/Q-62.70%
Insider Own0.40%Inst Own90.40%
Insider Trans-5.61%Inst Trans0.24%
Short Float13.01%EarningsApr 29/b
Analyst Recom2.30Target Price12.61
Avg Volume1.04M52W Range6.27 - 19.43
May-02-16 04:04PMThe 52-Week Low Club for Monday at 24/7 Wall St.
May-02-16 10:51AMImmunoGen (IMGN) Posts Wider-than-Expected Q3 Loss Zacks
May-02-16 08:17AMImmunoGen, Inc. breached its 50 day moving average in a Bearish Manner : IMGN-US : May 2, 2016 at Capital Cube
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugates technology. It offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. The company's clinical stage anticancer compounds include IMGN853 for the treatment of ovarian cancer, endometrial cancer, and other cancers, as well as IMGN529 and coltuximab ravtansine for the treatment of diffuse large B-cell lymphoma and other B-cell malignancies; and preclinical stage compounds comprise IMGN779 for the treatment of acute myeloid leukemia and myelodysplastic syndrome. It also develops BT-062 for multiple myeloma; BAY 94-9343 for mesothelioma and ovarian cancers; SAR650984 that is in Phase II clinical trials for multiple myeloma; AMG 595, which is in Phase I clinical trials for glioblastoma; and SAR566658 Phase I clinical trials for CA6-positive solid tumors. In addition, the company develops AMG 172 that is in Phase I clinical trials for clear cell renal cell carcinoma; SAR408701, which is in Phase I clinical trials for CEACAM5-positive solid tumors; LOP628 that is in Phase I clinical trial for c-Kit-positive cancers; and PCA062, which is in Phase I clinical trial for P-cadherin-positive cancers. ImmunoGen, Inc. has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; the Roche Group; Sanofi; Merck; and Takeda, as well as research agreement with CytomX Therapeutics to develop probody-drug conjugates against a specified number of cancers. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAMBERT JOHNExecutive Vice PresidentFeb 26Option Exercise4.8510,88952,796117,746Feb 26 03:21 PM
LAMBERT JOHNExecutive Vice PresidentFeb 01Option Exercise3.193,88912,406110,746Feb 01 01:28 PM
LAMBERT JOHNExecutive Vice PresidentFeb 01Sale8.223,88931,971106,857Feb 01 01:28 PM
Gregory Richard J.Executive VP & CSOJan 08Sale11.102,36926,30522,631Jan 11 10:03 AM
LAMBERT JOHNExecutive Vice PresidentJan 04Option Exercise3.193,88912,406110,746Jan 04 04:09 PM
CompanyK2M Group Holdings, Inc.
IndustryMedical Appliances & Equipment
Market Cap663.68MEPS (ttm)-0.98
P/E-EPS this Y41.10%
Forward P/E-EPS next Y85.90%
PEG-EPS past 5Y0.00%
P/S3.07EPS next 5Y20.00%
P/B2.28EPS Q/Q30.60%
Dividend-Sales Q/Q9.90%
Insider Own0.40%Inst Own65.10%
Insider Trans-1.55%Inst Trans0.05%
Short Float4.96%EarningsMay 02/a
Analyst Recom1.80Target Price25.29
Avg Volume224.80K52W Range11.15 - 26.29
May-03-16Downgrade Northland Capital Outperform → Market Perform
May-02-16 05:11PMK2M Group reports 1Q loss AP
May-02-16 04:17PMK2M GROUP HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
May-02-16 04:04PM4:04 pm K2M Group misses by $0.02, reports revs in-line; guides FY16 revs below consensus
May-02-16 04:01PMK2M Group Holdings, Inc. Reports First Quarter 2016 Financial Results, Led by U.S. Revenue Growth of 20% year-over-year, and Updates 2016 Outlook GlobeNewswire
May-02-16 07:07AMQ1 2016 K2M Group Holdings Inc Earnings Release - After Market Close CCBN
K2M Group Holdings, Inc., a medical device company, focuses on designing, developing, and commercializing proprietary complex spine technologies and techniques in the United States and internationally. It provides implants, disposables, and instruments primarily to hospitals for use by spine surgeons to treat spinal pathologies, such as deformity, trauma, and tumor. The company's complex spine products comprise MESA and MESA 2 deformity spinal, EVEREST deformity spinal, MESA rail deformity spinal, Cricket deformity, Quicket deformity, CAPRI corpectomy cage, DENALI deformity spinal, MESA small stature spinal, MESA rail small stature spinal, MESA mini spinal, SERENGETI complex spine minimally invasive retractor, RAVINE complex spine lateral access, and SANTORINI corpectomy cage systems, as well as NILE alternative fixation technology. Its minimally invasive spine products consist of SERENGETI minimally invasive retractor, RAVINE lateral access, CASCADIA lateral interbody, ALEUTIAN lateral interbody, TERRA NOVA minimally invasive access, EVEREST minimally invasive spinal and XT spinal systems. In addition, the company's degenerative spine products consist of EVEREST degenerative spinal, CASCADIA AN and TL interbody, ALEUTIAN interbody, RHINE cervical disc, CHESAPEAKE interbody, PYRENEES cervical plate, and BLUE RIDGE hybrid cervical plate systems, as well as BaseCamp rod reduction technology. It markets its products under the ALEUTIAN, Basecamp, BLUE RIDGE, CAPRI, CASCADIA, CASPIAN, CAYMAN, CHESAPEAKE, Deformity Cricket, DENALI, EVEREST, Lamellar Titanium Technology, MESA, NILE, PYRENEES, Quicket, Rail 4D Technology, RAVINE, RHINE, SANTORINI, SERENGETI, TERRA NOVA, and tifix names. The company promotes, markets, and sells its products through direct sales employees independent agencies, and distributor partners. K2M Group Holdings, Inc. was founded in 2004 and is headquartered in Leesburg, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Major Eric DPresident & CEOMar 10Option Exercise5.7343,630250,000103,907Mar 11 01:18 PM
FERRER CARLOS ADirectorMar 07Buy12.8438,942500,01539,382Mar 07 03:34 PM
Cole Gregory SChief Financial OfficerNov 12Option Exercise5.7320,245116,00429,332Nov 13 04:43 PM
Cole Gregory SChief Financial OfficerNov 12Sale19.3120,245390,9319,087Nov 13 04:43 PM
Cole Gregory SChief Financial OfficerNov 11Option Exercise5.7321,329122,21530,416Nov 13 04:43 PM
1 2 3 next